Google, Biogen team up on MS research: report

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec ($BIIB) will team up with online overlord Google ($GOOG) to sift through a mountain of data on the topic, according to a report from Bloomberg. The big goal for Biogen, a leader in the field, is to get a better idea of why some patients see the disease progress so much faster than others. And if it's successful, they could get information that will help guide prescribing existing drugs as well as develop new ones. This is Google X labs' second big pharma collaboration. Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.